Accession Number:

AD1122441

Title:

Anti complement Therapy to Improve Mortality and Morbidity for Traumatic Hemorrhage during Prolonged Field Care and Prolonged Damage Control Resuscitation

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

GENEVA FOUNDATION TACOMA WA

Personal Author(s):

• Li, Yansong

Report Date:

2020-10-01

Pagination or Media Count:

9

Abstract:

Bleeding hemorrhage after trauma remains a leading cause of death. Traumatic hemorrhage TH causes early innate immune response and clotting disorders. An inappropriate innate immune response after TH leads to an abnormal release of inflammatory mediators that contribute to early inflammation-mediated multi-organ failure MOF and death. Complement cascade ComC as a first line defense and a master alarm system of the innate immunity, represents a key mechanism to prime overzealous cytokine storm and thromboinflammation that contribute to multi-system inflammatory syndrome MSIS-mediated MOF after TH. The purpose of this study is to develop and validate anti-ComC therapies aimed at mitigating the MSIS-induced MOF and increasing survival, thereby improving outcomes during prolonged field care andor prehospital scenario for TH patients.

Descriptors:

• health services
• medical personnel
• therapy
• arteries
• hemorrhagic shock
• lung diseases
• diseases and disorders
• hemorrhage
• abstracts
• employment
• inflammation
• shock tubes
• wounds and injuries
• cytokines
• data analysis
• department of defense
• resuscitation
• veins
• blast injuries
• contracts

Subject Categories:

Distribution Statement:

[A, Approved For Public Release]